Novo Nordisk launches D2C platform, drops price of Wegovy for cash-pay patients: The move could start a marketing showdown—and possible price war—between Novo and Lilly.
Patients value digital health tools, but adoption lags at many medical practices: It’s now tablestakes for healthcare orgs to have a digital front door that allows consumers to use online tools to access care.
AbbVie shakes up obesity market: AbbVie’s entrance to the weight loss drug market could create more competition between Big Pharma with a vote of confidence in a GLP-1 alternative.
It launches with 200+ partners, aiming to reshape enterprise workflows—but adoption hurdles like trust issues and integration complexity could slow its impact.
Eli Lilly’s Oscars commercial slams unapproved drugs like compounded GLP-1s: The ad could help pharma companies rebuild trust with consumers.
Medical misinformation ‘infodemic’ on social media: Influencers are promoting misleading information about medical tests. Here’s what healthcare and pharma brands should be doing to combat it.
Microsoft, Google enhance genAI offerings for clinicians: We examine the race between startups, health tech companies, and Big Tech giants to show healthcare organizations how their AI tools will drive efficiency-–and why Microsoft could have a leg up on the competition.
What Gen Z wants from pharma: We present the data on how Gen Z feels about pharma communications and explore how marketers can more effectively reach younger consumers.
Healthcare stakeholders push Congress to make Medicare coverage of telehealth permanent: It’s set to expire at the end of March. We explore what’s at stake for seniors, many of whom are used to getting care remotely.
Placing Aria Gen 2 in research labs could help Meta gather real-world data—turning researchers into de facto product testers for its next wave of consumer smart glasses.
Doctors should ask their patients to write online reviews—and then respond to feedback: It will go a long way in attracting and retaining patients.
Trump issues executive order to make healthcare prices more transparent: Price rules finalized during his first term haven’t had an impact. Could it be different this time around?
Talks of a Walgreens take-private sale are ramping up again: Walgreens could be divided into three parts if the sale proceeds. We explore the likelihood of a deal going through and what it means for Walgreens’ future.
Only 18% of consumers have ever asked their doctor about a drug ad: But when they do, many patients walk away with a prescription for that medication. We explore how pharma marketers can get the most out of their ad campaigns.
Hims & Hers will still sell compounded semaglutide to some patients: The company isn’t ready to admit defeat in the battle between compounded GLP-1 sellers and Big Pharma. But Hims’ competitive advantage in the weight loss drug market is getting weaker.
US docs spend up to 3 hours per week correcting AI: Physicians’ liability concerns with AI can be addressed by having them involved with technology purchasing decisions.
DOJ will examine UnitedHealth’s Medicare billing practices: The Trump administration has made “waste, fraud, and abuse” a rallying cry. Now, we find out how serious they are about it.
The Ozempic shortage is over: We explore how an FDA decision impacts compounded weight loss drug sellers like Hims & Hers and patients who are prescribed GLP-1s.
HHS instructs CDC to shelve vaccine ads, including for the flu: RFK Jr. was at the helm of a decision to halt the CDC’s vaccine-focused advertisements—an early indicator of the steps he’s willing to take in his new role as HHS Secretary.
Hims & Hers moves into at-home testing: Its recent acquisition of a small lab testing company could have a big payoff.